Despite a relatively high tumor mutation burden (TMB), ICB is ineffective in most patients with SCLC, regardless of whether the regimen targets the PD-1/PD-L1 axis alone or is combined with anti-CTLA-4 (Antonia et al., 2016; Ott et al., 2017). The gene discussed is CD274; the disease is neoplasm.